BTCC / BTCC Square / Global Cryptocurrency /
Eli Lilly Eyes €15 Billion French Biotech Deal as Weight Loss Drugs Drive Record Revenue

Eli Lilly Eyes €15 Billion French Biotech Deal as Weight Loss Drugs Drive Record Revenue

Published:
2026-01-12 10:21:01
15
3
BTCCSquare news:

Eli Lilly is positioning for a major European expansion with a potential €15 billion acquisition of French biotech firm Abivax. The deal hinges on French regulatory clarity regarding foreign investment controls, with the pharmaceutical giant awaiting guidance from France's Finance Ministry before submitting a formal offer.

The company's financial firepower stems largely from its blockbuster weight loss treatments. Tirzepatide has dethroned Merck's Keytruda as the world's top-selling drug, generating $24.8 billion in revenue through September 2025. Pipeline candidates show even greater promise—Retatrutide demonstrated industry-leading 28.7% mean weight loss in Phase 3 trials, while oral treatment Orforglipron secured fast-track approval with potential launch by February 2026.

Despite trading at 33 times forward earnings, Lilly's PEG ratio of 0.98 suggests the premium valuation may be justified by growth prospects. The Abivax acquisition WOULD mark a strategic diversification beyond metabolic treatments into immunology and inflammatory diseases.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.